Pre-made Brodalumab benchmark antibody ( Whole mAb, anti-IL17RA/IL17R therapeutic antibody, Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brodalumab (trade name Siliq in the US and Kyntheum in Europe) is a human monoclonal antibody designed for the treatment of inflammatory diseases.
| Products Name (INN Index) | Pre-Made Brodalumab biosimilar, Whole mAb, Anti-IL17RA/IL17R Antibody: Anti-CANDF5/CD217/CDw217RAR/IMD51/hIL-17R therapeutic antibody |
|---|---|
| INN Name | Brodalumab |
| Target | IL17RA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2011 |
| Year Recommended | 2012 |
| Companies | Amgen,AstraZeneca,Bausch Health Companies,Kyowa Hakko Kirin,LEO Pharma |
| Conditions Approved | Erythrodermic psoriasis,Plaque psoriasis,Psoriatic arthritis,Pustular psoriasis,Psoriasis |
| Conditions Active | Axial Spondylarthritis,Systemic scleroderma,Palmoplantar pustulosis |
| Conditions Discontinued | Asthma,Crohn's disease,Rheumatoid arthritis |
| Development Tech | Abgenix XenoMouse |
| Previous Name | NA |
| Gm Offical Target Name | IL17RA/IL17R |
| Package |
